生物制剂在口腔扁平苔藓治疗中的应用

doi:10.13591/j.cnki.kqyx.2022.03.014

摘要/Abstract

摘要： 口腔扁平苔藓(oral lichen planus,OLP)是一种病因不明、与自身免疫密切相关的慢性炎性疾病。皮质类固醇和免疫抑制剂是治疗OLP的常用药物,但部分OLP患者表现为不敏感或治疗抵抗。有研究提示生物制剂对治疗常规药物治疗不敏感或抵抗的OLP患者显示出优势。该文就治疗OLP生物制剂的种类、机制、疗效、预后及不良反应作一综述,为OLP的治疗提供参考。

关键词: 口腔扁平苔藓, 生物制剂, 治疗

Abstract: Oral lichen planus (OLP) is a chronic inflammatory disease of unknown etiology, and is closely related to autoimmunity. Corticosteroids and immunosuppressants are commonly used drugs for OLP treatment, but some OLP patients show insensitivity or treatment resistance. Research suggests that biologics have advantages for OLP patients that are not sensitive or are resistant to conventional drug treatment. This article reviews the types, mechanisms, efficacy, prognosis, and adverse reactions of biologics for OLP treatment and provides references for the treatment of OLP.

Key words: oral lichen planus, biologics, treatment

中图分类号:

R781.5

孙雨桐, 江潞. 生物制剂在口腔扁平苔藓治疗中的应用[J]. 口腔医学, 2022, 42(3): 261-265.

SUN Yutong, JIANG Lu. Role of biologics in the treatment of oral lichen planus[J]. Stomatology, 2022, 42(3): 261-265.

参考文献

[1] Olson MA, Rogers RSⅢ, Bruce AJ. Oral lichen planus[J]. Clin Dermatol, 2016, 34(4):495-504.
[2] Alrashdan MS, Cirillo N, McCullough M. Oral lichen planus:A literature review and update[J]. Arch Dermatol Res, 2016, 308(8):539-551.
[3] Carrozzo M, Porter S, Mercadante V,et al. Oral lichen planus:A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies[J]. Periodontol 2000, 2019, 80(1):105-125.
[4] Nogueira PA, Carneiro S, Ramos-e-Silva M. Oral lichen planus:An update on its pathogenesis[J]. Int J Dermatol, 2015, 54(9):1005-1010.
[5] Kurago ZB. Etiology and pathogenesis of oral lichen planus:An overview[J]. Oral Surg Oral Med Oral Pathol OralRadiol, 2016, 122(1):72-80.
[6] Gupta S, Ghosh S, Gupta S. Interventions for the management of oral lichen planus:A review of the conventional and novel therapies[J]. Oral Dis, 2017, 23(8):1029-1042.
[7] Rønholt K, Iversen L. Old and new biological therapies for psoriasis[J]. Int J Mol Sci, 2017, 18(11):E2297.
[8] Speeckaert R, Lambert J, van Geel N. Learning from success and failure:Biologics for non-approved skin diseases[J]. Front Immunol, 2019, 10:1918.
[9] Joly P, Maho-Vaillant M, Prost-Squarcioni C,et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of Pemphigus (Ritux 3):A prospective, multicentre, parallel-group, open-label randomised trial[J]. Lancet, 2017, 389(10083):2031-2040.
[10] Torres J, Mehandru S, Colombel JF,et al. Crohn's disease[J]. Lancet, 2017, 389(10080):1741-1755.
[11] Heelan K, McAleer MA, Roche L,et al. Intractable erosive lichen planus treated successfully with rituximab[J]. Br J Dermatol, 2015, 172(2):538-540.
[12] Mahmoud MM, Afifi MM. Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus[J]. Eur J Oral Sci, 2016, 124(2):119-126.
[13] Fivenson DP, Mathes B. Treatment of generalized lichen planus with alefacept[J]. Arch Dermatol, 2006, 142(2):151-152.
[14] Chang AL, Badger J, Rehmus W,et al. Alefacept for erosive lichen planus:A case series[J]. J Drugs Dermatol, 2008, 7(4):379-383.
[15] Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab[J]. Arch Dermatol, 2006, 142(6):680-682.
[16] Heffernan MP, Smith DI, Bentley D,et al. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus[J]. J Drugs Dermatol, 2007, 6(3):310-314.
[17] Jones-Hughes T, Snowsill T, Haasova M,et al. Immunosuppressive therapy for kidney transplantation in adults:A systematic review and economic model[J]. Health Technol Assess, 2016, 20(62):1-594.
[18] Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft:A systematic review and meta-analysis[J]. Clin Exp Nephrol, 2018, 22(3):684-693.
[19] Rebora A, Parodi A, Murialdo G. Basiliximab is effectivefor erosive lichen planus[J]. Arch Dermatol, 2002, 138(8):1100-1101.
[20] MacIsaac J, Siddiqui R, Jamula E,et al. Systematic review of rituximab for autoimmune diseases:A potential alternative to intravenous immune globulin[J]. Transfusion, 2018, 58(11):2729-2735.
[21] Parmentier L, Bron BA, Prins C,et al. Mucocutaneous lichen planus with esophageal involvement:Successful treatment with an anti-CD20 monoclonal antibody[J]. Arch Dermatol, 2008, 144(11):1427-1430.
[22] Salles G, Barrett M, Foà R,et al. Rituximab in B-cell hematologic malignancies:A review of 20 years of clinical experience[J]. Adv Ther, 2017, 34(10):2232-2273.
[23] Mitoma H, Horiuchi T, Tsukamoto H, et al. Molecular mechanisms of action of anti-TNF-α agents-Comparison among therapeutic TNF-α antagonists[J]. Cytokine, 2018, 101:56-63.
[24] Yarom N. Etanercept for the management of oral lichen planus[J]. Am J Clin Dermatol, 2007, 8(2):121.
[25] Campanati A, Diotallevi F, Martina E,et al. Safety update of etanercept treatment for moderate to severe plaque psoriasis[J]. Expert Opin Drug Saf, 2020, 19(4):439-448.
[26] O'Neill ID, Scully C. Biologics in oral medicine:Ulcerative disorders[J]. Oral Dis, 2013, 19(1):37-45.
[27] Chao TJ. Adalimumab in the management of cutaneous and oral lichen planus[J]. Cutis, 2009, 84(6):325-328.
[28] Holló P, Szakonyi J, Kiss D,et al. Successful treatment of lichen planus with adalimumab[J]. Acta Derm Venereol, 2012, 92(4):385-386.
[29] Inoue-Nishimoto T, Hanafusa T, Igawa K, et al. Possible association of anti-tumor necrosis factor-α antibody therapy with the development of scleroderma-like changes with lichen planus[J]. Eur J Dermatol, 2015, 25(5):513-515.
[30] Inoue A, Sawada Y, Yamaguchi T, et al. Lichenoid drug eruption caused by adalimumab:A case report and literature review[J]. Eur J Dermatol, 2017, 27(1):69-70.
[31] Li MG, Kroetz DL. Bevacizumab-induced hypertension:Clinical presentation and molecular understanding[J].Pharmacol Ther, 2018, 182:152-160.
[32] Chiang CP, Yu-Fong Chang J, Wang YP,et al. Oral lichen planus-Differential diagnoses, serum autoantibodies, hematinic deficiencies, and management[J]. J Formos Med Assoc, 2018, 117(9):756-765.
[33] 傅志华, 武照, 李乾鹏, 等. 血管生成与口腔扁平苔藓关系的研究进展[J]. 口腔医学, 2019, 39(8):757-761.
[34] Succaria F, Bhawan J. Cutaneous side-effects of biologics in immune-mediated disorders:A histopathological perspective[J]. J Dermatol, 2017, 44(3):243-250.
[35] Andrade P, Lopes S, Albuquerque A, et al. Oral lichen planus in IBD patients:A paradoxical adverse effect of anti-TNF-α therapy[J]. Dig Dis Sci, 2015, 60(9):2746-2749.